Testovis provides testosterone propionate a derivate of the primary endogenous androgen testosterone, for intramuscular administration.
Testosterone propionate is indicated for androgen replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism: Testicular failure due to cryptorchisdism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectonly.
Delayed puberty: Testosterone propionate may be used to stimulate puberty in carefully selected males with clearly delayed puberty.
Metastatic mammary cancer: testosterone propionate may be used secondarily in women with advancing inoperable metastatie mammary cancer who are one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone/responsive tumor.
Endogenous androgens are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as alterations in body musculature; and fat distribution.
Androgens are responsible for the growth spurt of adolescence and for the eventual termination of linear growth, which is brought about by fusion of the epiphysis growth centers. In children, exogenous androgens accelerate linear growth rates but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of growth process. Androgens have been reported to stimulate the production of red blood cells by enhancing the production of erythropoietic stimulating factor.
During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH).
When administrated concurrently, the following drugs may interact with androgens, such as Methandrostenolone, have been reported to decrease the anticoagulant requirement. Patients receiving oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Usual dose is 50 to 100 mg, 3 times a week. Many experts prefer to use the shorter acting androgen preparations rather than those with prolonged activity for treating breast carcinoma, particularly during the early stages of androgen therapy.